HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

RB 007

antidote for RB006

Also Known As:

RB-007; RB007 compound; anivamersen

Networked: 4 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Nucleic Acids, Nucleotides, and Nucleosides: 1
- Nucleotides: 15763
  - Polynucleotides: 218
    - Oligonucleotides: 5145
      - RB 007: 4

Experts

1.	Becker, Richard C: 3 articles (01/2016 - 12/2009)
2.	Alexander, John H: 2 articles (01/2016 - 08/2014)
3.	Cohen, Mauricio G: 2 articles (01/2016 - 08/2014)
4.	Cornel, Jan H: 2 articles (01/2016 - 08/2014)
5.	Kasprzak, Jaroslaw D: 2 articles (01/2016 - 08/2014)
6.	Mehran, Roxana: 2 articles (01/2016 - 08/2014)
7.	Povsic, Thomas J: 2 articles (01/2016 - 08/2014)
8.	Zelenkofske, Steven L: 2 articles (01/2016 - 08/2014)
9.	Alexander, David: 1 article (02/2016)
10.	Alexander, John: 1 article (02/2016)

Related Diseases

1.	Acute Coronary Syndrome 08/01/2014 - "We sought to determine the feasibility of conducting percutaneous coronary intervention (PCI) in high-risk acute coronary syndrome (ACS) patients utilising the REG1 system consisting of pegnivacogin, an aptameric factor IXa inhibitor, and its controlling agent anivamersen. "
2.	Thrombosis (Thrombus) 12/01/2009 - "REG-1, a regimen comprising RB-006, a Factor IXa antagonist, and its oligonucleotide active control agent RB-007 for the potential treatment of arterial thrombosis." 12/01/2009 - "REG-1, under development by Regado Biosciences Inc, is an intravenously administered anticoagulant system comprising the Factor IXa-inhibiting aptamer RB-006 and its complementary active control oligonucleotide, RB-007, for the potential treatment of arterial thrombosis. "
3.	Infarction (Infarctions) 02/01/2016 - "However, in contrast to heparin-treated baboons, those receiving pegnivacogin/anivamersen displayed thrombi in the bypass cannulae upon cannulation and kidney cortical infarcts. "
4.	Hemorrhage 01/01/2016 - "We tested the hypothesis that near complete inhibition of factor IXa with pegnivacogin during percutaneous coronary intervention, followed by partial reversal with anivamersen, would reduce ischaemic events compared with bivalirudin, without increasing bleeding. "
5.	Coronary Artery Disease (Coronary Atherosclerosis) 12/01/2009 - "In phase I clinical trials in healthy volunteers and patients with stable coronary artery disease, RB-006 inhibited Factor IXa activity, an effect that was titratibly reversible by the application of RB-007. "

Related Drugs and Biologics

1.	RB 006
2.	Factor IXa (Coagulation Factor IXa)
3.	Oligonucleotides
4.	Heparin (Liquaemin)
5.	Anticoagulants
6.	bivalirudin (Angiomax)
7.	A-factor (Streptomyces)

Related Therapies and Procedures

1.	Percutaneous Coronary Intervention
2.	Cannula